Results 101 to 110 of about 749,314 (382)

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

New England Journal of Medicine, 2017
Background Imatinib, a selective BCR‐ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow‐up in patients with CML who were ...
A. Hochhaus, R. Larson, F. Guilhot, J. Radich, S. Branford, T. Hughes, M. Baccarani, M. Deininger, F. Cervantes, Satoko Fujihara, C. Ortmann, H. Menssen, H. Kantarjian, S. O’Brien, B. Druker   +14 more
semanticscholar   +1 more source

The Regulation of Trace Metal Elements in Cancer Ferroptosis

Advanced Biology, EarlyView.
The induction of ferroptosis inhibits tumor growth, enhances anticancer efficacy, and overcomes drug resistance. Recent evidence shows nonferrous metal elements play a role in ferroptosis. This review focuses on how trace metals regulate ferroptosis processes like iron accumulation, lipid peroxidation, and antioxidant defense.
Xiaoyan Wang, Yuanyuan Xue, Lei Chang, Xuena Zhu, Wenjun Liu, Tingbo Liang   +5 more
wiley   +1 more source

Chromosomal breaks at the origin of small tandem DNA duplications

BioEssays, Volume 45, Issue 1, January 2023., 2023
Small tandem DNA duplications form a specific mutational signature frequently found in human disease alleles and cancer genes. Here we hypothesize that these duplications mainly arise at chromosomal DNA breaks that result from two closely located single‐stranded nicks, through error‐prone repair by the non‐homologous end‐joining pathway. Abstract Small
Joost Schimmel, Marloes D. van Wezel, Robin van Schendel, Marcel Tijsterman   +3 more
wiley   +1 more source

Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity

Haematologica, 2008
Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell ...
Désirée Bonci, Maria Musumeci, Valeria Coppola, Antonio Addario, Concetta Conticello, Michael Hahne, Massimo Gulisano, Francesco Grignani, Ruggero De Maria   +8 more
doaj   +1 more source

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

New England Journal of Medicine, 2018
BACKGROUND Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next‐generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value
M. Jongen‐Lavrencic, T. Grob, Diana Hanekamp, F. Kavelaars, A. A. Al Hinai, A. Zeilemaker, Claudia A. J. Erpelinck-Verschueren, P. Gradowska, R. Meijer, J. Cloos, B. Biemond, C. Graux, M. van Marwijk Kooy, M. Manz, T. Pabst, J. Passweg, V. Havelange, G. Ossenkoppele, M. Sanders, G. Schuurhuis, B. Löwenberg, P. Valk   +21 more
semanticscholar   +1 more source

Engineering Novel DNA Nanoarchitectures for Targeted Drug Delivery and Aptamer Mediated Apoptosis in Cancer Therapeutics

Advanced Functional Materials, EarlyView.
Designer DNA Architecture‐templated Drug Conjugates (DDA‐DCs) are comprised of a DNA nanomaterial decorated with multiple drug‐loaded DNA aptamers. DDA‐DCs use a combination of multiple aptamer types, each recognizing a different membrane protein to achieve precise targeting of cancer cells.
Abhisek Dwivedy, Dhyanesh Baskaran, Gaurav Sharma, Wei Hong, Dhanush Gandavadi, Abhichart Krissanaprasit, Joonsu Han, Yusheng Liu, Zack Zimmers, Tshepo Mafokwane, Ichrak Hayah, Neha Chauhan, Mengxi Zheng, Sherwood Yao, Keith Fraser, John S. Decker, Xiaohe Jin, Hua Wang, Adam D. Friedman, Xing Wang   +19 more
wiley   +1 more source

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

Haematologica, 2008
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara, Rossana Maffei, Silvia Martinelli, Annalisa Arcari, Federico Piacentini, Elena Trabacchi, Pierluigi Alfieri, Angela Ferrari, Giovanna Leonardi, Gabriele Luppi, Giuseppe Longo, Daniele Vallisa, Roberto Marasca, Giuseppe Torelli   +13 more
doaj   +1 more source

Immunophenotypes of Acute Myeloid Leukemia From Flow Cytometry Data Using Templates [PDF]

arXiv, 2014
Motivation: We investigate whether a template-based classification pipeline could be used to identify immunophenotypes in (and thereby classify) a heterogeneous disease with many subtypes. The disease we consider here is Acute Myeloid Leukemia, which is heterogeneous at the morphologic, cytogenetic and molecular levels, with several known subtypes. The
arxiv  

Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]

, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan ...
arxiv   +1 more source

Chronic myeloid leukemia in Asia

International Journal of Hematology, 2008
Chronic myeloid leukemia (CML) in Asia has an incidence rather lower than in Western countries yet tends to afflict a younger population. As in the West, imatinib mesylate (IM, Glivec) has supplanted busulphan, hydroxyurea and interferon-alpha as first-line treatment.
Jootar, S, Kim, DW, O'Neil, WM, Caguioa, PB, Kweon, IY, Hsu, SC, Chuah, C, Saikia, TK, Au, WY, Wang, J   +9 more
openaire   +4 more sources